TGFB1 and renal fibrosis: Silymarin nanoliposomes exhibited in vivo therapeutic potential in attenuating DN evidenced by decreasing renal fibrosis, inflammation and oxidative stress in DN rats mediated through TGF-β/Smad and JAK2/STAT3/suppressor of cytokine signaling (SOCS)1 co-suppression, leading to improved survival rate (70).